KFDA approves arthritis treatment Orencia

Published: 2010-04-02 06:57:00

Updated: 2010-04-02 06:57:00

The Korea Food and Drug Administration said on Mach 29 it has granted final approval to Bristol-Myers Squibb's (BMS) Orencia — a potential blockbuster arthritis treatment, according to BMS Korea.

Administered intravenously, Orencia is a first-in-class selective co-stimulation modulator designe...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK